Bulletin
Investor Alert

April 21, 2021, 10:47 p.m. EDT

Global Interleukin-33 inhibitors Market Outlook, Industry Analysis and Prospect 2021

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Apr 21, 2021 (Heraldkeepers) -- DelveInsight's, "Interleukin-33 inhibitors – Pipeline Insight, 2021," report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Interleukin-33 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

GET FREE SAMPLE REPORT : https://www.wiseguyreports.com/sample-request/6654341-interleukin-33-inhibitors-pipeline-insight-2021

Geography Covered
? Global coverage

Interleukin-33 inhibitors Understanding
Interleukin-33 inhibitors: Overview
IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.

SHARE YOUR QUERIES : https://www.wiseguyreports.com/enquiry/6654341-interleukin-33-inhibitors-pipeline-insight-2021

Report Highlights
? The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-33 inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin-33 inhibitors.

REPORT DETAILS :

https://www.wiseguyreports.com/reports/6654341-interleukin-33-inhibitors-pipeline-insight-2021

Interleukin-33 inhibitors Emerging Drugs Chapters
This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-33 inhibitors Emerging Drugs
? MEDI3506: AstraZeneca
MEDI3506 is an IL-33 (interleukin-33) inhibiting monoclonal antibody being developed by AstraZeneca. The drug is currently in Phase II clinical studies for the treatment of COPD, atopic dermatitis, asthma, COVID-19 infection, and diabetic kidney disease.

? Itepekimab: Regeneron Pharmaceuticals/Sanofi
Itepekimab (REGN3500) is a fully-human monoclonal antibody that inhibits interleukin-33. The drug is being studied in Phase III trials for asthma, chronic obstructive pulmonary disease. REGN3500 was invented using Regeneron’s proprietary VelocImmune technology that yields optimized fully-human antibodies, and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement.
Further product details are provided in the report........

Interleukin-33 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
? Major Players working on Interleukin-33 inhibitors
There are approx. 7+ key companies which are developing the Interleukin-33 inhibitors. The companies which have their Interleukin-33 inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals/Sanofi.

? Phases
DelveInsight's report covers around 7+ products under different phases of clinical development like
? Late-stage products (Phase III and
? Mid-stage products (Phase II and
? Early-stage products (Phase I/II and Phase I) along with the details of
? Pre-clinical and Discovery stage candidates
? Discontinued & Inactive candidates

? Route of Administration
Interleukin-33 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
? Infusion
? Intradermal
? Intramuscular
? Intranasal
? Intravaginal
? Oral
? Parenteral
? Subcutaneous
? Topical

? Molecule Type
Products have been categorized under various Molecule types such as
? Vaccines
? Monoclonal Antibody
? Peptides
? Polymer
? Small molecule

? Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-33 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.

Interleukin-33 inhibitors Report Insights
? Interleukin-33 inhibitors Pipeline Analysis
? Therapeutic Assessment
? Unmet Needs
? Impact of Drugs

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.